HeartBeam director granted 51,724 stock options

HeartBeam, Inc. director Willem Elfrink received a stock option grant covering 51,724 shares of common stock on February 9, 2026.

Rhea-AI Filing Summary

HeartBeam, Inc. director Willem Elfrink received a stock option grant covering 51,724 shares of common stock on February 9, 2026. The options have an exercise price of $1.43 per share and expire on January 1, 2036.

According to the vesting terms, half of the shares subject to this “Special Option” vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent Elfrink’s reported derivative holdings following this award.

Insider Trade Summary

Grant/Award: 51,724 shares

Grant/Award 1 txn

Insider Elfrink Willem

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock (right to buy)	51,724	$0.00	$0.00

Holdings After Transaction: Common Stock (right to buy) — 51,724 contracts (Direct)

Footnotes (1)

1. F1. Granted options on February 9, 2026 (the "Special Option"), one half of the total number of shares of common stock (the "Shares") subject to the Special Option shall vest on March 31, 2026, the three-month anniversary of the vesting commencement date beginning January 1, 2026, and the remaining Shares of common stock shall vest on June 30, 2026, the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HeartBeam (BEAT) report for Willem Elfrink?

HeartBeam reported that director Willem Elfrink received a stock option grant for 51,724 shares on February 9, 2026. These options give him the right to buy HeartBeam common stock at a fixed exercise price under the company’s 2022 Equity Incentive Plan.

How many HeartBeam (BEAT) shares are covered by Willem Elfrink’s new options?

The grant covers options on 51,724 shares of HeartBeam common stock. This entire amount is reported as his derivative holdings after the transaction, meaning the filing shows one new grant rather than multiple separate option awards.

What is the exercise price of Willem Elfrink’s HeartBeam (BEAT) option grant?

The options have an exercise price of $1.43 per share. This means Elfrink can purchase HeartBeam common stock at $1.43 for each share covered by the option, subject to the vesting schedule and the stated expiration date of January 1, 2036.

When do Willem Elfrink’s HeartBeam (BEAT) options vest?

Half of the 51,724 options vest on March 31, 2026, and the remaining half vest on June 30, 2026. The vesting schedule is based on a vesting commencement date of January 1, 2026, creating two equal vesting tranches three and six months later.

What is the expiration date of the HeartBeam (BEAT) options granted to Willem Elfrink?

The options granted to Elfrink expire on January 1, 2036. After that date, any unexercised options will lapse. The long term to expiration gives a multi-year window in which vested options can potentially be exercised, subject to applicable plan and company rules.

Under which plan were Willem Elfrink’s HeartBeam (BEAT) options issued?

The options were issued under HeartBeam’s 2022 Equity Incentive Plan. This plan is used to grant equity-based compensation such as stock options to directors and other participants, aligning their interests with shareholders through potential future ownership in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 05:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elfrink Willem

(Last) (First) (Middle)

2118 WALSH AVE

SUITE 210

(Street)

SANTA CLARA CALIFORNIA 95050

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HeartBeam, Inc. [ BEAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (right to buy)	$1.43	02/09/2026		A		51,724		(1)	01/01/2036	Common Stock	51,724	$0	51,724	D

Explanation of Responses:

1. Granted options on February 9, 2026 (the "Special Option"), one half of the total number of shares of common stock (the "Shares") subject to the Special Option shall vest on March 31, 2026, the three-month anniversary of the vesting commencement date beginning January 1, 2026, and the remaining Shares of common stock shall vest on June 30, 2026, the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan.

	/s/ Willem Elfrink	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)